Salute e Benessere
Bridge to Life™ Unveils Groundbreaking 12-Month Clinical Trial Data on HOPE at World Transplant Congress 2025
The following are scheduled presentations at WTC 2025:
Hypothermic-Oxygenated and Normothermic Machine Perfusion: A Risk-Matched Post-Hoc Comparison of the Bridge to Hope Randomized Trial with Prospectively Collected Institutional Outcomes
Monday, August 4 10:30 AM -10:45 AM PT
Chase J. Wehrle, MD, Cleveland Clinic,
Cleveland, OH
Impact of Hypothermic Oxygenated Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: Stratified Analysis Based on Donor Age
Monday, August 4 3:30 PM -4:30 PM PT
Marco Maria Pascale , MD, Fondazione Policlinico Universitario Agostino Gemelli,
Rome, Italy
Mitochondrial Injury and Function Comparing Hypothermic and Normothermic Machine Perfusion of Human Livers
Tuesday, August 5 3:30 PM-4:30 PM PT
Omer Faruk Karakaya, MD, Department of Inflammation and Immunity, Lerner Research Institute - Cleveland Clinic,
Cleveland, OH
: Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation
Tuesday, August 5 5:26 PM -5:35 PM PT
David Axelrod , MD, University Hospitals Cleveland Medical Center, OH
Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation
Wednesday, August 6 9:20 AM -9:29 AM PT
David J. Reich , MD, FACS,
Drexel University , Philadelphia, PA
Novel Approach to Viability Assessment of Split Liver Grafts Using Hypothermic Oxygenated Perfusion
Sunday, August 3 3:11 PM -3:20 PM PT
Geofia Crasta, MD, Cleveland Clinic - Lerner Research Institute,
Cleveland, OH
Clinical and Logistical Impact of Machine Perfusion in a Low Volume Liver Transplant Center
Sunday, August 3 3:20 PM -3:29 PM PT
Marco Maria Pascale, MD, Fondazione Policlinico Universitario Agostino Gemelli,
Rome, Italy
Immunomodulation through Hypothermic Oxygenated Perfusion in Liver Transplantation: Biomarker Analysis in Peripheral Blood
Tuesday, August 5 8:15 AM -9:30 AM PT
Marco Maria Pascale , MD, Policlinico Universitario Fondazione Agostino Gemelli,
Rome, Italy
Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: A Multicenter Study
Wednesday, August 6 10:09 AM –
10:18 AM PT
Francisco Hernández Oliveros, MD, La Paz Hospital,
Madrid, Spain
Bridge to Life™ will also be sponsoring a symposium on
Monday, August 4, 2025 , 7:00 – 8:00 AM PDT on
The symposium will take place in the Moscone Center, Room 307.
: Garret Roll , MD,
University of California San Francisco , San Francisco, CA
:
David Axelrod , MD, University Hospitals Cleveland Medical Center, OH
David Foley , University of Wisconsin School of Medicine and Public Health,
Madison, WI
Andrea Schlegel , MD, Cleveland Clinic Foundation,
Cleveland, OH
Bridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW , EasiSlush and the VitaSmart™ Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally.
VitaSmart™ is CE Marked and available for sale in several markets outside of the United States . VitaSmart™ is pending FDA approval in the United States .
Logo - https://mma.prnewswire.com/media/2085277/Bridge_to_Life_New_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bridge-to-life-unveils-groundbreaking-12-month-clinical-trial-data-on-hope-at-world-transplant-congress-2025-302504781.html